Olema Pharmaceuticals, Inc. (OLMA)
| Market Cap | 1.08B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 39.56M |
| EPS (ttm) | -2.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 458,279 |
| Open | 28.90 |
| Previous Close | 28.75 |
| Day's Range | 27.25 - 29.00 |
| 52-Week Range | 19.41 - 60.27 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 56.00 (+104.5%) |
| Est. Earnings Date | Nov 9, 2021 |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Ph...
Financial Performance
Financial StatementsNews
Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference
SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...
Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SAN FRANCISCO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference
SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development ...
Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update
SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development ...
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...
Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...
Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
SAN FRANCISCO, March 17, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developmen...
Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Ann...
SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci...
Olema Oncology to Participate at Upcoming Virtual Investor Conferences
SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
Analyst talks Biotech sector, offers three picks for 2021
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable i...
Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...
Olema Trading $34 Above IPO Price After Only 2 Weeks
Since going public on Nov. 19, shares of Olema Pharmaceuticals Inc.(NASDAQ:OLMA) have soared past the offering price of $19 per share to over $53, giving the San Francisco-based company a market value o...
Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Add...
SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...
Olema Oncology Announces Pricing of Initial Public Offering
SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercia...